UBS Group’s Amylyx Pharmaceuticals AMLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $8.03M | Sell |
1,253,344
-135,083
| -10% | -$866K | ﹤0.01% | 2617 |
|
|
2025
Q1 | $4.92M | Buy |
1,388,427
+744,903
| +116% | +$2.64M | ﹤0.01% | 2969 |
|
|
2024
Q4 | $2.43M | Buy |
643,524
+414,448
| +181% | +$1.57M | ﹤0.01% | 3570 |
|
|
2024
Q3 | $742K | Buy |
229,076
+198,937
| +660% | +$645K | ﹤0.01% | 3811 |
|
|
2024
Q2 | $57.3K | Sell |
30,139
-180,434
| -86% | -$343K | ﹤0.01% | 5446 |
|
|
2024
Q1 | $598K | Buy |
210,573
+171,559
| +440% | +$487K | ﹤0.01% | 3957 |
|
|
2023
Q4 | $574K | Buy |
39,014
+34,403
| +746% | +$506K | ﹤0.01% | 3878 |
|
|
2023
Q3 | $84.4K | Sell |
4,611
-69,464
| -94% | -$1.27M | ﹤0.01% | 4827 |
|
|
2023
Q2 | $1.6M | Buy |
74,075
+27,522
| +59% | +$594K | ﹤0.01% | 2874 |
|
|
2023
Q1 | $1.37M | Buy |
46,553
+43,076
| +1,239% | +$1.26M | ﹤0.01% | 2929 |
|
|
2022
Q4 | $128K | Sell |
3,477
-510
| -13% | -$18.8K | ﹤0.01% | 4760 |
|
|
2022
Q3 | $112K | Buy |
3,987
+3,810
| +2,153% | +$107K | ﹤0.01% | 4567 |
|
|
2022
Q2 | $3K | Sell |
177
-3,980
| -96% | -$67.5K | ﹤0.01% | 8231 |
|
|
2022
Q1 | $53K | Buy |
+4,157
| New | +$53K | ﹤0.01% | 5408 |
|